Treatment Information

Back

Lung Cancer treatment details. Chemotherapy.

University of Kansas Medical Center, Kansas City, Kansas, United States.

Survival: monthsCountry:United States
Toxiciy Grade:4City/State/Province:Kansas City, Kansas
Treatments:ChemotherapyHospital:University of Kansas Medical Center
Drugs:Journal:Link
Date:Dec 2005

Description:

Patients: This Phase III study involved a total of 367 patients. Patients were divided into two groups: Group A had 181 patients and Group B had 186 patients. The median age for patients in Group A was 63 and there were 115 men and 66 were women. The majority had stage IV cancer. For Group B, the median age was also 63 and there 117 men and 69 women. The majority had stage IV cancer.

Treatment: The treatment for patients in Group B consisted of two chemotherapeutic drugs -- paclitaxel and carboplatin.

Toxicity: There were seven treatment related deaths in Group B. In addition grade 3-4 toxicities included: hearing loss, visual disturbances, gastrointestinal toxicities, myalgia, and neutropenic fever.

Results: The median survival for Group B was 9.0 months.

Support: One author had received honoraria and had acted as a consultant for Sanofi and one author had received honoraria from Bristol-Myers Squibb. Taxol is manufactured by Bristol-Myers Squibb. Sanofi is developing tirapazamine.



Back